Methods for the treatment of thyroid eye disease
The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
1. A method of reducing proptosis by at least 2 mm in a subject with thyroid eye disease (TED),
comprising administering to the subject an effective amount of an antibody, or an antigen binding fragment thereof, comprising a heavy chain comprising CDR1, CDR2 and CDR3 and a light chain comprising CDR1, CDR2 and CDR3, as set forth in SEQ ID NOs: 1-6, respectively, wherein the antibody specifically binds and inhibits insulin-like growth factor I receptor (IGF-IR),
wherein the antibody is administered at a dosage of about 1 mg/kg to about 5 mg/kg antibody as a first dose, or
wherein the antibody is administered at a dosage of about 5 mg/kg to about 10 mg/kg antibody as a first dose.
2. The method of claim 1 , wherein proptosis is reduced by at least 3 mm.
3. The method of claim 2 , wherein proptosis is reduced by at least 4 mm.
4. The method of claim 1 , wherein the method additionally comprises reducing the clinical activity score (CAS) in the subject with TED.
5. The method of claim 4 , wherein CAS is reduced by at least 2 points.
6. The method of claim 5 , wherein CAS is reduced by at least 3 points.
7. The method of claim 6 , wherein proptosis is reduced by at least 3 mm and CAS is reduced by at least 3 points.
8. The method of claim 1 , wherein the TED is active TED.
9. The method of claim 1 , wherein the TED is moderate-to-severe TED.
10. The method of claim 1 , wherein the TED is active, moderate-to-severe TED.
11. The method of claim 1 , wherein the antibody is administered at a dosage of about 1 mg/kg to about 5 mg/kg antibody as a first dose.
12. The method of claim 1 , wherein the antibody is administered at a dosage of about 5 mg/kg to about 10 mg/kg antibody as a first dose.
13. The method of claim 12 , wherein the antibody is administered at a dosage of about 5 mg/kg to about 20 mg/kg antibody in subsequent doses.
14. The method of claim 13 , wherein the antibody is administered in the following amounts:
about 10 mg/kg antibody as a first dose; and
about 20 mg/kg antibody in subsequent doses.
15. The method of claim 13 , wherein the subsequent doses are administered every three weeks for at least 21 weeks.
16. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, has a binding affinity (K D ) of 10 −8 M or less for the IGF-1R.
17. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, has a binding affinity (K D ) of 10 −13 to 10 −9 M for the IGF-1R.
18. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, has IC 50 values for the binding of IGF-I and IGF-II to IGF-IR of no more than 2 nM.
19. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, comprises a heavy chain variable region having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 8.
20. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
21. The method of claim 1 , wherein the antibody is teprotumumab, or an antigen binding fragment thereof.
22. The method of claim 1 , wherein the antibody is teprotumumab.
23. The method of claim 1 , wherein the antibody, or an antigen binding fragment thereof, is a human antibody, a monoclonal antibody, a human monoclonal antibody, a purified antibody, a diabody, a single-chain antibody, a multi-specific antibody, Fab, Fab′, F(ab′)2, Fv, or scFv.
24. The method of claim 1 , wherein the treatment is efficacious for at least 20 weeks beyond the last administered dose.